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Abstract
Introduction: Postmenopausal women manifest emotional disorders associated with an increase in appetite. 
The aim of the study was to assess the serotonin and melatonin secretion and metabolism in postmenopausal women in relation to eat-
ing disorders. 
Material and methods: Sixty postmenopausal women and 30 women without hormonal disturbances were enrolled into the study and 
divided into three groups: group I (control) – women without menstrual disorders, group II — postmenopausal women without appetite 
disorders and change in body weight, and group III — postmenopausal women with increased appetite and weight gain. Serum melatonin, 
serotonin, urinary 6-sulfatoxymelatonin (aMT6s), and 5-hydroxyindoleacetic acid (5-HIAA) excretion were measured. 
Results: Serum serotonin and melatonin levels in groups II and III were lower compared to group I. Urinary 5-HIAA and aMT6s excretion 
was lower in overweight women. In group III the correlation between the serum level of serotonin, melatonin, and BMI was negative; 
a high statistical significance was found between BMI and urinary aMT6s excretion.
Conclusions: Melatonin supplementation and use of drugs modulating the serotonin homeostasis together with female hormones have 
a beneficial effect in complex treatment of disorders of eating in postmenopausal women. (Endokrynol Pol 2016; 67 (3): 299–304)
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Streszczenie
Wstęp: U kobiet po menopauzie często spotykamy zaburzenia emocjonalne oraz wzrost apetytu.
Celem badań była ocena wydzielania i metabolizmu serotoniny i melatoniny u kobiet w okresie pomenopauzalnym z zaburzeniami 
odżywiania. 
Materiały i metody: Badanie przeprowadzono w grupie 60 kobiet po menopauzie i 30 przed menopauzą (grupa kontrolna). Wśród kobiet 
po menopauzie wyodrębniono dwie podgrupy — kobiety ze wzrostem apetytu i masy ciała oraz bez nich. Procedury diagnostyczne 
obejmowały ocenę stanu odżywienia, określenie stężenia melatoniny i serotoniny w surowicy krwi oraz ich matabolitów — siarczanu 
6-metoksymelatoniny (aMT6s) oraz kwasu 5-hydroksy-indolooctowego (5-HIAA) w moczu. 
Wyniki: Stwierdzono, że stężenie serotoniny i melatoniny w surowicy krwi w grupach pacjentek po menopauzie było niższe niż u kobiet 
przed menopauzą. Wydalenie metabolitów serotoniny i melatoniny z moczem było najniższe u otyłych kobiet po menopauzie. U tych 
pacjentek stwierdzono ujemną korelację między stężeniem serotoniny w surowicy krwi, stężeniem melatoniny oraz BMI; a także istotną 
statystycznie zależność pomiędzy wydalaniem aMT6s z moczem a BMI.
Wnioski: U kobiet w okresie pomenopauzalnym wydzielanie serotoniny i melatoniny jest zmniejszone, co należy uwzględnić w kom-
pleksowej terapii i prewencji zaburzeń łaknienia i odżywienia. (Endokrynol Pol 2016; 67 (3): 299–304)
Słowa kluczowe: serotonina; melatonina; kobiety po menopauzie; zaburzenia odżywiania
Introduction 
Postmenopausal women often manifest emotional dis-
orders associated with weakness or increase in appetite 
[1, 2]. These changes may lead to reduction in body 
weight or more frequently to obesity [3–5]. 
Perimenopausal depression and obesity are impor-
tant health problems [6]. The temporal relationship of 
mental disorders and appetite does not raise doubts, 
but common pathogenetic factors are still searched 
for. Among them, not only the decrease of the level of 
oestrogen is taken into account but also the disruption 
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of homeostasis of other hormones and neuromodula-
tors [7]. Alterations in serotonergic neuronal function in 
the central nervous system are commonly considered 
to be one of the causes of depression [8]. Serotonin also 
plays an important role in the regulation of appetite [9]. 
For these reasons drugs modulating serotonin reuptake 
have found application in the treatment of both depres-
sion and obesity [10, 11].
The role of melatonin is less known in this aspect. 
First research studies revealed that secretion of mela-
tonin was higher in women with both anorexia nervosa 
and bulimia than in the control groups [12]. However, 
experimental studies demonstrated increased insulin 
resistance, development of glucose intolerance, and 
weight gain in pinealectomised rats [13]. It was also 
shown that melatonin supplementation in animals with 
induced obesity had a positive effect on the secretion 
of leptin and adiponectin and on the level of glucose, 
cholesterol, and triglycerides [14, 15]. Melatonin and its 
analogues have been introduced into the treatment of 
mood disorders and hyperalimentation in humans [16]. 
Serotonin is the substrate in the synthesis of melatonin. 
Its secretion is subject to similar processes of circadian and 
seasonal variations, and it also shows correlation with the 
age of the respondents [17] and the secretory activity of 
the gonads, but opinions on this subject are not consistent 
[18] and it requires further research.
The aim of our study was to assess serotonin and 
melatonin secretion and metabolism in postmenopausal 
women in relation to eating disorders. 
Material and methods
Sixty women were enrolled into the study, a minimum 
of three years after their menopause, aged 53–63 years 
and 30 women in whom clinical examinations excluded 
hormonal disturbances and any diseases.
Three groups were distinguished:
 — Group I (control, n = 30) — healthy women without 
menstrual disorders
 — Group II (n = 30) — postmenopausal women with-
out appetite disorders and change in body weight
 — Group III (n = 30) — postmenopausal women ex-
periencing, at that time, increased appetite by mini-
mum 3 points in a 10-point VAS scale and weight 
gain by minimum 10% of the due weight. 
The clinical examination determined, among other 
things, the level of anxiety using the Hamilton Anxiety 
Rating Scale (HARS) and the severity of depression 
using the Beck Depression Inventory (BDI), and imag-
ing examinations were performed (endoscopy, USG, 
CT) as well as the following laboratory tests: blood cell 
count, CRP, bilirubin, alanine (ALT) and aspartate (AST) 
aminotransferase, gamma-glutamyl transpeptidase 
(GGT), amylase, lipase, urea, creatinine, cholesterol, 
triglycerides, and glycated haemoglobin.
17-b-oestradiol concentration in serum was meas-
ured by the ELISA test (antibodies Ortho — Clinical 
Diagnostic) and follicle-stimulating hormone (FSH) 
concentration in serum was also measured by Elisa test 
(antibodies Vitros Products).
Exclusion criteria: other organic and metabolic 
diseases, past surgeries, severe anxiety (over 24 points 
in HARS) and/or depression (more than 15 points in 
BDI) according to the German criteria, Helicobacter pylori 
infection, the use of hormone replacement therapy, or 
other pharmacotherapy.
Seven days prior to the evaluations, all medications 
were withdrawn and the patients remained on the same 
diet containing tryptophan-rich products. On the day 
of the study the patients were administered the same 
liquid diet (Nutridrink-Nutricia) in the amount of 3 × 
× 400 ml, containing 18.9 g carbohydrate, 6.0 g protein, 
5.8 g lipid/100 mL, of total caloric value 1800 kcal, and 
1500 ml of isotonic still water. Blood samples were 
drawn from the antecubital vein at 08:00 and serum 
was frozen at –70oC. On the same day, the 24-hour urine 
collection was performed and the samples were kept 
at 4oC. At the end of 24-hour collection, the volume of 
urine was measured and the samples were frozen at 
–70oC. Serum melatonin and urinary 6-sulfatoxyme-
latonin (aMT6s) concentration were measured by the 
ELISA method applying IBL antibodies (RE-54021 and 
RE-54031, Nordic Immunological Laboratories, Tilburg, 
Holland) and Expert 99 MicroWin 2000 Reader (BMG 
Labtech, Offenburg, Germany)
Serum serotonin and urinary 5-hydroxyindoleacetic 
acid (5-HIAA) were measured using the ELISA method 
applying an IBL kit (RE 59121 and RE 59131).
Statistical analysis
The nonparametric Kruskal-Wallis test was used in the 
statistical analysis to compare serotonin and melatonin 
levels and urinary 5-HIAA and aMT6s excretion. The 
Mann-Whitney test was applied for median compari-
son. The correlation between the above parameters and 
the body mass index was estimated with the Pearson’s 
correlation coefficient and linear regression equation. 
STATISTICA 9.1 software (AxAP106E735914191-F li-
cense) was used for the calculations.
Results
Fasting serum serotonin level differed in the group of 
postmenopausal women compared to the control group 
and it was in group I — 142.3 ± 38.1 ng/mL, in group 
II — 129.6 ± 23.7 ng/mL (p < 0.05), in group III — 117.7 
± 27.9 ng/mL (p < 0.01) (Table I, Fig. 1).
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However, urinary 5-HIAA excretion was lower only 
in overweight women, and it was: in the control group 
6.05 ± 2.11 mg/24 hours and in group III — 3.99 ± 1.04 
mg/24 h (p < 0.05) (Fig. 2).
Serum melatonin level was: in group I — 9.13 ± 2.87 
pg/mL, in group II — 6.55 ± 2.47 pg/mL (p < 0.05), and 
in group III — 5.75 ± 1.53 pg/mL (p < 0.01) (Fig. 3).
Similar differences were observed in relation to 
urinary aMT6s excretion — respectively –11.32 ± 4.42 
µg/24 hours, 8.84 ± 2.76 µg/24 hours (p < 0.01), 7.90 ± 
± 2.97 µg/24 hours (p < 0.001) (Fig. 4).
In the control group, a weak, statistically insignifi-
cant negative correlation was noted between the above-
mentioned parameters and body mass index (Table II).
 In the group of postmenopausal women with nor-
mal body weight, a similar negative correlation was 
detected, but it was of significance only in relation to 
the urinary aMT6s excretion (r = –0.5662, p < 0.05) 
(Table II, Fig. 5). 
In group III (women with overweight), the cor-
relation between the serum level of serotonin and 
melatonin and BMI was also negative, and it was, 
respectively: r = –0.5241 and r = –0.4906 (Table II). 
However, a high statistical significance (r = –0.87632) 
Table I. General characteristics of women enrolled in the study
Tabela I. Charakterystyka ogólna kobiet uczestniczących 
w badaniu
Feature Group I Group II Group III
Age (years) 32,4 ± 3,1 57,2 ± 1,8 56,9 ± 4,0
BMI [kg/m2] 21,7 ± 1,7 21,6 ± 1,8 30,5 ± 3,6
HARS (points) 10,5 ± 6,1 19,2 ± 3,4 18,4 ± 2,9
BDI (points) 6,6 ± 2,9 16,2 ± 2,4 17,1 ± 2,0
17-b-oestradiol [pg/mL] 51,0 ± 16,3 16,8 ± 4,9 18,3 ± 5,2
FSH [mlU/mL] 14,5 ± 5,4 80,3 ± 19,0 76,5 ± 17,6
GFR [ml/min] 104,8 ± 10,2 98,8 ± 6,9 96,5 ± 12,3
BMI — body mass index; HARS — Hamilton Anxiety Rating Scale; BDI — Beck 
Depression Inventory; FSH — follicle stimulating hormone; GFR — glomerular 
filtration rate
Figure 1. Serum levels of serotonin in healthy women (group I), 
postmenopausal women without disorders of eating (group II), 
and with overweight (group III);  ± SD, *p < 0.05, **p < 0.01
Rycina 1. Stężenie serotoniny w surowicy zdrowych kobiet (grupa I), 
u kobiet po menopauzie bez zaburzeń odżywiania (grupa II) oraz 
kobiet z nadwagą (grupa III);  ± SD, *p < 0,05, **p < 0,01
Figure 2. Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion 
in healthy women (group I), postmenopausal women without 
disorders of eating (group II), and with overweight (group III); 
 ± SD, *p < 0.05
Rycina 2. Wydalanie kwasu 5-hydroksyindolooctowego (5-HIAA) 
z moczem u zdrowych kobiet (grupa I), u kobiet po menopauzie, 
bez zaburzeń jedzenia (grupa II) oraz z nadwagą (grupa III);  
± SD, *p < 0,05
Figure 3. Serum levels of melatonin in healthy women (group I), 
postmenopausal women without disorders of eating (group II), 
and with overweight (group III); 
 ± SD, *p < 0.05; **p < 0.01
Rycina 3. Stężenia melatoniny u zdrowych kobiet (grupa I), 
u kobiet po menopauzie bez zaburzeń jedzenia (grupa II) oraz 
z nadwagą (grupa III);  ± SD, *p < 0,05; **p < 0,01
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was found between BMI and urinary aMT6s excretion, 
respectively (Table II, Fig. 6).
Discussion
Serotonin plays an important role in the regulation of 
hunger and satiety. In the central and peripheral nerv-
ous system, its synthesis and secretion increase under 
the effect of b-adrenergic and muscarinic stimulation 
[19], but also under the influence of oestrogens [20]. In 
the gastrointestinal tract enterochromaffin cells are the 
Table II. Correlation between body mass index (BMI) and 
serotonin (SER) and melatonin (MEL) serum levels as well 
as urinary excretion of 5-hydroxyindoloacetic acid (5-HIAA) 
and 6-sulfatoxymelatonin (aMT6s);  ± SD, *p < 0.05, 
**p < 0.001
Tabela II. Korelacja między wskaźnikiem masy ciała (BMI) 
a stężeniem serotoniny (SER) i melatoniny (MEL) w surowicy 
oraz wydalaniem z moczem kwasu 5-hydroksyindolooctowego 
(5-HIAA) i 6-sulfatoksymelatoniny (aMT6s);  ± SD, *p < 0,05, 
**p < 0,001
Correlation Correlation coefficient (r)
Group I Group II Group III
SER
BMI
–0.4042 –0.2379 –0.5241*
5-HIAA –0.4881 –0.4326 –0.4483
MEL –0.3318 –0.3563 –0.4906
aMT6s –0.3774 –0.5662* –0.8763**
Figure 6. Correlation between urinary 6-sulfatoxymelatonin 
(aMT6s) excretion and body mass index (BMI) in postmenopausal 
women with overweight (group III);  ± SD, *p < 0.05
Rycina 6. Korelacja między wydalaniem 6-sulfatoksymelatoniny 
(aMT6s) z moczem a wskaźnikiem masy ciała (BMI) u kobiet po 
menopauzie z nadwagą (grupa III);  ± SD, *p < 0,05
Figure 4. Urinary 6-sulfatoxymelatonin (aMT6s) excretion 
in healthy women (group I), postmenopausal women without 
disorders of eating (group II), and with overweight (group III); 
 ± SD, **p < 0.01
Rycina 4. Wydalanie 6-sulfatoksymelatoniny (aMT6s) z moczem 
u zdrowych kobiet (grupa I), u kobiet po menopauzie bez zaburzeń 
jedzenia (grupa II) oraz u kobiet po menopauzie z nadwagą (grupa 
III);  ± SD, **p < 0,01
Figure 5. Correlation between urinary 6-sulfatoxymelatonin 
(aMT6s) excretion and body mass index (BMI) in postmenopausal 
women without disorders of eating (group II);  ± SD, *p < 0.05
Rycina 5. Korelacja między wydalaniem 6-sulfatoksymelatoniny 
(aMT6s) z moczem a wskaźnikiem masy ciała (BMI) u kobiet po 
menopauzie bez zaburzeń odżywiania (grupa II;  ± SD, *p < 0,05 main source of serotonin, and the changes of physical 
conditions during digestive processes stimulate its 
secretion [21].
Serotonin exerts an inhibitory effect on CNS hunger 
centres [22]. Both oestrogen and serotonin levels are 
reduced in ovariectomised experimental animals, which 
results in rapid weight gain. This change can be pre-
vented by oestradiol supplementation [23]. Oestrogens 
exert an anorectic effect through increased production 
of serotonin in the CNS and cause increased satiety 
centre activity via cholecystokinin receptors [24]. An 
inhibitory effect of oestrogen on gastric motility [25], 
secretion [26], and stimulation of duodenal bicarbonate 
secretion are also possible. 
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Serotonin also demonstrates an inhibitory effect on 
the secretion of HCl [27], stimulating at the same time 
bicarbonate secretion [28]. This implies that the reduced 
levels of oestrogen and serotonin in postmenopausal 
women can stimulate gastric secretory and motor func-
tion and increase the feeling of hunger. The results of 
our research confirm such a direction and mechanism 
of changes. 
Melatonin also plays an important role in the control 
of appetite. Melatonin biosynthesis is mainly regulated 
by light but also by norepinephrine via beta-1-adrener-
gic receptors. The involvement of other factors, includ-
ing oestrogen, in the process of melatonin secretion is 
poorly recognised. Bodis et al. [29] demonstrated that 
melatonin suppresses oestradiol and progesterone 
secretion and may play a role in the regulation of the 
menstrual cycle. In turn, Luboshitzky et al. [30] found 
that a four-month oestradiol treatment reduces the uri-
nary 6-6-sulfatoxymelatonin (aMT6s) excretion. Gruber 
et al. [31] noted in women with secondary amenorrhea 
a negative correlation between the serum level of 17-b-
oestradiol and urinary aMT6s excretion. 
The results of our study and other investigations 
do not confirm such a correlation. Okatani et al. [32] 
found a negative correlation between peak (night) 
melatonin secretion and secretion of 17-b-oestradiol. At 
the same time, they showed that oral intake of oestro-
gen reduces the nocturnal secretion of melatonin. The 
above observations indicate that low levels of oestrogen 
after menopause should result in increased secretion 
of melatonin. 
Vakkuri et al. [33] detected in menopausal women 
a negative correlation between serum FSH and uri-
nary melatonin secretion at night. Furthermore, they 
observed that reduced melatonin secretion begins 
immediately after the age of 40 years and can initiate 
menopause. 
Bleicher et al. [34] observed in postmenopausal 
women lower urinary aMT6s excretion, particularly in 
the case of coexisting obesity and sleep disorders. 
However, a beneficial effect of melatonin on carbo-
hydrate and lipid metabolism indicators was demon-
strated in many experimental studies [35, 36]. Regula-
tion of these correlations leads to decreased appetite 
and weight reduction [37, 38]. 
The results of clinical studies also point to the cor-
relation between a low level of melatonin and obesity 
[39]. For this reason, a lot of authors suggest using 
melatonin in therapeutic procedures in obesity [40, 41].
Moreover, experimental studies showed that me-
latonin inhibits the secretion of hydrochloric acid and 
pepsin [42], stimulates the secretion of duodenal and 
pancreatic bicarbonates, and thus acts synergistically 
with serotonin. As a consequence, its deficiency can also 
lead to a drop of pH in the duodenum, stimulation of in-
sulin secretion, and increase of appetite. These changes 
are unfavourable and difficult to control, particularly 
at night. The coexisting sleep disorders, often occur-
ring in postmenopausal women, can also promote the 
phenomenon of “night snacking” and the development 
of hyperalimentation syndrome.
Changes in appetite are more common in women 
than in men, which points to a significant effect of 
oestrogens on the physiology of eating [43]. Oestrogen 
deficiency after menopause and the associated reduc-
tion in the synthesis of serotonin can also be the cause 
of emotional disorders [44]. 
Conclusions
All of the above facts and the results of our studies point 
to the need of use of drugs modulating serotonin ho-
meostasis and/or melatonin supplementation together 
with female hormones in the prevention and complex 
treatment of disorders of eating in postmenopausal 
women.
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